Ortho-McNeil Pharmaceutical, Inc. Ditches $625 Million Diabetes Drug Pact with Diamyd Medical AB
6/2/2011 8:24:34 AM
More...
|
Ortho-McNeil Pharmaceutical, Inc. Enters into Agreement with Watson Laboratories, Inc. (WPI) for CONCERTA(R) Authorized Generic
11/2/2010 7:34:57 AM
More...
|
Metabolex, Inc. Enters Into Type 2 Diabetes Development and License Agreement with Ortho-McNeil Pharmaceutical, Inc.; Metabolex Could be Eligible to Receive Development, Regulatory, and Commercial Milestones up to $330 Million
6/22/2010 7:15:21 AM
More...
|
Ortho-McNeil Pharmaceutical, Inc. Pleads Guilty to Illegal Promotion of Topamax and is Sentenced to Criminal Fine of $6.14 Million
5/24/2010 8:05:57 AM
More...
|
Ortho-McNeil Pharmaceutical, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
4/29/2010 11:39:29 AM
More...
|
FDA Issues Complete Response Letter for Ortho-McNeil Pharmaceutical, Inc.'s Rivaroxaban
5/28/2009 9:53:22 AM
More...
|
Ortho-McNeil Pharmaceutical, Inc. New Study Supports Use of LEVAQUIN as a Guideline-Concordant Antibiotic for the Treatment of Community-Acquired Pneumonia
10/27/2008 8:42:00 AM
More...
|
Isis Pharmaceuticals, Inc. (ISIS)Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil Pharmaceutical, Inc.
10/2/2007 10:33:00 AM
More...
|
FDA Approves Ortho-McNeil Pharmaceutical, Inc.'s LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
9/17/2007 6:57:52 AM
More...
|
Isis Pharmaceuticals, Inc. (ISIS) Licenses Experimental Diabetes Drugs to Ortho-McNeil Pharmaceutical, Inc. for $45 Million
9/13/2007 7:08:45 AM
More...
|
|